Lacosamid Viatris

Lacosamide, the active ingredient in Lacosamid Viatris, is an anticonvulsant presented as an oral formulation for oral use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used in the management of focal epilepsy, acting on neuronal excitability to control seizure activity.

Partial‑onset seizures (adults): adjunctive therapy to reduce seizure frequency. Partial‑onset seizures (adolescents): adjunctive therapy to reduce seizure frequency. Focal epilepsy: adjunctive treatment to improve overall seizure control.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Nausea - Headache - Somnolence - Diplopia - Fatigue

Serious or Rare Side Effects: - PR‑interval prolongation or other cardiac conduction abnormalities - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hypersensitivity reactions including anaphylaxis - Suicidal ideation or behavior - Significant hepatic enzyme elevations

When prescribing lacosamide, clinicians should consider several safety aspects.

Renal impairment: dose adjustment may be required based on renal function. Cardiac conduction disorders: monitor ECG in patients with existing heart disease. Concomitant CNS depressants: may increase sedation and dizziness. Pregnancy: safety data are limited; use only if benefit outweighs risk. Driving and operating machinery: patients should be cautioned about possible impairment. Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase lacosamide levels. - Strong CYP3A4 inducers (e.g., carbamazepine) may reduce lacosamide efficacy. - Other sodium‑channel blockers may potentiate CNS effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) may modestly raise concentrations. - Alcohol: may enhance sedation and dizziness. - Certain antiepileptics (e.g., phenobarbital) may alter plasma levels.